Barclays PLC Acquires 62,354 Shares of Definitive Healthcare Corp. (NASDAQ:DH)

Barclays PLC lifted its holdings in Definitive Healthcare Corp. (NASDAQ:DH) by 318.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 81,916 shares of the company’s stock after purchasing an additional 62,354 shares during the period. Barclays PLC’s holdings in Definitive Healthcare were worth $366,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its stake in Definitive Healthcare by 17.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,896 shares of the company’s stock worth $125,000 after acquiring an additional 3,332 shares during the period. Principal Financial Group Inc. raised its stake in Definitive Healthcare by 10.8% during the 2nd quarter. Principal Financial Group Inc. now owns 39,856 shares of the company’s stock worth $218,000 after acquiring an additional 3,874 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Definitive Healthcare by 31.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,292 shares of the company’s stock worth $116,000 after acquiring an additional 5,083 shares during the period. Glenmede Trust Co. NA raised its stake in Definitive Healthcare by 41.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 18,423 shares of the company’s stock worth $82,000 after acquiring an additional 5,362 shares during the period. Finally, Point72 DIFC Ltd raised its stake in Definitive Healthcare by 759.9% during the 3rd quarter. Point72 DIFC Ltd now owns 9,296 shares of the company’s stock worth $42,000 after acquiring an additional 8,215 shares during the period. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Trading Up 5.8 %

DH stock opened at $4.36 on Friday. The firm has a fifty day moving average price of $4.37 and a 200 day moving average price of $4.58. Definitive Healthcare Corp. has a fifty-two week low of $3.19 and a fifty-two week high of $10.62. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. The firm has a market cap of $503.68 million, a PE ratio of -1.41, a price-to-earnings-growth ratio of 3.29 and a beta of 1.40.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on DH shares. BTIG Research started coverage on shares of Definitive Healthcare in a report on Tuesday, September 17th. They set a “buy” rating and a $7.00 price objective for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a report on Friday, November 8th. Finally, Stephens started coverage on shares of Definitive Healthcare in a report on Friday, December 20th. They set an “equal weight” rating and a $5.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $5.72.

Insider Activity at Definitive Healthcare

In other Definitive Healthcare news, insider William Moschella sold 45,000 shares of Definitive Healthcare stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $4.70, for a total transaction of $211,500.00. Following the completion of the transaction, the insider now directly owns 433,830 shares of the company’s stock, valued at $2,039,001. The trade was a 9.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.84% of the stock is currently owned by insiders.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.